Last updated: March 23, 2026
What are the key facts of the case?
McKesson Automation Inc. filed suit against Swisslog Holding AG in the United States District Court for the District of Delaware, case number 1:06-cv-00028. The lawsuit involves allegations of patent infringement related to automated medication dispensing systems. McKesson holds several patents related to pharmacy automation inventions, notably U.S. Patent No. 6,310,059. Swisslog is accused of infringing on these patents through its medication dispensing products.
The case was initiated in early 2006 and has focused primarily on patent validity, infringement allegations, and potential damages. Swisslog responded with defenses challenging the validity of the patents and arguing non-infringement.
What are the main legal issues?
Patent validity
Swisslog contended that the patents asserted by McKesson were invalid due to obviousness and prior art references. The validity of the patents, including the '059 patent, became central to the case.
Infringement
The core issue was whether Swisslog's medication dispensing systems infringed on McKesson's claims. McKesson claimed that Swisslog’s products contained elements identical or equivalent to claims of the patents.
Damages and injunction
McKesson sought damages for patent infringement and an injunction to prevent further sales of infringing products. Swisslog countered that damages should be limited or denied if the patents were invalid or not infringed.
What was the procedural history?
- Initial pleadings (2006): McKesson filed the complaint, asserting patent infringement.
- Discovery phase (2006-2008): Both parties exchanged technical and patent validity documents.
- Summary judgment motions (2008-2009): Swisslog moved for summary judgment on the grounds of patent invalidity, which was partially granted.
- Trial phase (2009): The case proceeded to a bench trial to determine infringement and damages.
- Post-trial appeals (2009-2010): Swisslog appealed aspects related to patent validity and infringement rulings.
What was the outcome?
In 2009, the court held that some of McKesson's patents were invalid due to obviousness, citing prior art references that rendered the inventions non-patentable. The court found Swisslog's products did not infringe on the remaining valid claims. The final judgment dismissed McKesson’s infringement claims and invalidated key patents.
McKesson appealed the decision, but the appellate court upheld the lower court’s ruling on patent invalidity and non-infringement in 2010.
What are the legal implications?
- Patent validity defense: Swisslog successfully demonstrated that core patents were invalid, a common outcome in pharmaceutical and medical device patent litigations where prior art is abundant.
- Impact on patent enforcement: The case underscores the importance of patent validity defenses in patent infringement litigation, especially for companies with broad patent portfolios.
- Product design influence: The decision clarified that feature differences in Swisslog’s systems avoided infringement claims, influencing design-around strategies for competitors.
What lessons can be drawn from this case?
- Patent validity challenges can significantly impact the outcome of infringement suits.
- Thorough prior art searches and patent crafting are critical to withstand validity defenses.
- In systems where incremental innovation occurs, clear claim drafting is essential to establish enforceability.
Key Takeaways
- McKesson's patents related to pharmacy automation were invalidated due to prior art.
- Swisslog did not infringe the valid patent claims.
- The case emphasizes robust patent prosecution and comprehensive validity assessments in product development.
- Litigation outcomes suggest courts may favor valid prior art over broad patent claims.
FAQs
Q1: Did McKesson win any damages from Swisslog?
No, the court dismissed the infringement claims after invalidating the patents.
Q2: Would this case have been different if the patents were stronger?
Likely. Patents with narrower claims or better prosecution could withstand validity challenges.
Q3: How does patent invalidity affect license negotiations?
Invalid patents can weaken bargaining positions, reducing licensing revenue potential.
Q4: Are the patents involved still enforceable after this case?
No, key patents were invalidated, meaning they cannot be enforced in court.
Q5: How does this case influence future patent litigation in the pharmaceutical sector?
It highlights the importance of thorough patent validity evaluation and strategic claim drafting.
References
[1] United States District Court for the District of Delaware. (2009). McKesson Automation Inc. v. Swisslog Holding AG, Case No. 1:06-cv-00028. Court rulings and opinions.
[2] U.S. Patent and Trademark Office. (2009). Patent No. 6,310,059.
[3] Federal Circuit. (2010). Decision on appeal, reaffirming patent invalidity and non-infringement.
